FDA issues EUA for Regeneron's COVID-19 mAb cocktail
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on November 21 for the casirivimab and imdevimab monoclonal antibody (mAb) cocktail. The mAb cocktail is for the treatment of mild to moderate symptoms in patients with COVID-19 who are at a high risk for progressing to severe COVID-19.
Immunomic, Colmmune partner on cancer immunotherapy
Immunomic Therapeutics and CoImmune Therapeutics have entered into a license agreement for Immunomic to use CoImmune's proprietary dendritic cell process for certain Immunomic cell therapy vaccine programs.
Lilly, Precision BioSciences collaborate on genome editing
Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome editing platform for potential in vivo therapies for genetic disorders.
Oxford/AstraZeneca COVID-19 vaccine strongly efficacious in older adults
Similar safety and immunogenicity profiles were observed in adults and older adults who received the Oxford/AstraZeneca SARS-CoV-2 vaccine candidate, ChAdOx1 nCoV-19, according to data from the phase II clinical trial. The findings were published in the Lancet on November 18.  Discuss
Particles for Humanity wins $5M Gates Foundation grant
Particles for Humanity has secured a $5 million grant from the Bill & Melinda Gates Foundation, which it plans to use to develop a single injection vaccine delivery technology.
Megadalton joins Waters' Immerse Cambridge labs
Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Umoja Biopharma to develop in vivo immunotherapy platform
Umoja Biopharma has completed $53 million in series A financing to support development of its in vivo immunotherapy platform.
Obsidian, MD Anderson partner on solid tumor cell therapy
Obsidian Therapeutics and the University of Texas MD Anderson Cancer Center have entered a multiyear strategic collaboration for the research and development of novel engineered tumor infiltrating lymphocytes for the treatment of solid tumors.
Vivet, Pfizer to begin Wilson's disease gene therapy trial
The U.S. Food and Drug Administration (FDA) has cleared Vivet Therapeutics' investigational new drug application for the Gateway study, a phase I/II study evaluating Vivet's VTX-801, a proprietary, investigational gene therapy for the treatment of Wilson's disease.
Samsung Biologics breaks ground on 'super plant'
Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter